Clinical Efficacy of Imeglimin (Twymeeg) for Elderly Patient with Type 2 Diabetes Mellitus (T2DM)
Open Access
- 21 February 2022
- journal article
- Published by Asploro Open Access Publications in Asploro Journal of Biomedical and Clinical Case Reports
- Vol. 5 (1), 33-37
- https://doi.org/10.36502/2022/asjbccr.6259
Abstract
Background: As an oral hypoglycaemic agent (OHA), imeglimin (Twymeeg) has been recently introduced to clinical practice for patients with type 2 diabetes mellitus (T2DM) as Twymeeg. It has beneficial pharmacological mechanisms, which are improving insulin secretion, increasing insulin sensitivity, and decreasing insulin resistance. Case Presentation: The case is 84-year-old man with mild cognitive impairment (MCI) for 3 years. He visited late August, 2021 our clinic for general malaise and was pointed out to have post-prandial blood glucose 336 mg/dL and HbA1c 8.6%. He was diagnosed with T2DM. Results: He was started to be given imeglimin 1000mg twice a day, and then HbA1c value was decreased to 7.3% in 4 weeks and 5.7% in 8 weeks. During 9-12 weeks, he felt loss of appetite and reduced food intake. Biochemical examination on 12 weeks showed decreased values of TP, Alb, HbA1c, glucose, free T3, and normal values of TSH, free T4. Doses of imeglimin were 500 mg twice a day for 9-12 weeks and discontinued after 12 weeks. Discussion: Regarding appetite loss, possible causes may include MCI, previous history of gallbladder dyskinesia, adverse effect of imeglimin, and so on. Further development of research will be expected for imeglimin in the future.Keywords
This publication has 14 references indexed in Scilit:
- Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trialsDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021
- ImegliminClinical Diabetes, 2021
- A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathwayJournal of Diabetes Investigation, 2021
- Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practiceTherapeutic Advances in Endocrinology and Metabolism, 2021
- The International Diabetes Federation’s guide for diabetes epidemiological studiesDiabetes Research and Clinical Practice, 2020
- Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trialDiabetes, Obesity and Metabolism, 2020
- Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetesDiabetes, Obesity and Metabolism, 2020
- A review of phenformin, metformin, and imegliminDrug Development Research, 2020
- The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin MonotherapyDiabetes Care, 2014
- Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patientsDiabetes, Obesity and Metabolism, 2012